| Recruiting | Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment- Treatment-resistant Schizophrenia | Phase 3 | 2026-01-23 |
| Completed | Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia Schizophrenia | Phase 2 | 2020-06-16 |
| Unknown | An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects Healthy | Phase 1 | 2018-04-02 |
| Terminated | Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms Rett Syndrome | Phase 2 / Phase 3 | 2016-10-26 |
| Completed | A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia Chronic Schizophrenia | Phase 2 | 2015-12-01 |
| Completed | A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers. Schizophrenia | Phase 1 | 2013-06-01 |
| Completed | Safinamide Renal Impairment Trial Renal Impairment | Phase 1 | 2011-06-01 |
| Terminated | A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging Parkinson Disease | Phase 2 | 2011-03-01 |
| Completed | A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Dis Parkinson's Disease With Cognitive Impairments | Phase 2 | 2010-09-01 |
| Completed | Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects Parkinson's Disease | Phase 2 | 2010-04-01 |
| Terminated | MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Idiopathic Parkinson's Disease | Phase 3 | 2009-10-01 |
| Completed | A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics Idiopathic Parkinson's Disease | Phase 1 / Phase 2 | 2009-09-01 |
| Terminated | Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients Parkinson's Disease | Phase 3 | 2009-04-01 |
| Completed | A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics Hepatic Impairment | Phase 1 | 2009-04-01 |
| Completed | Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain Pain | Phase 3 | 2009-03-20 |
| Completed | Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa Idiopathic Parkinson's Disease | Phase 3 | 2009-02-01 |
| Completed | MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Idiopathic Parkinson's Disease | Phase 3 | 2007-11-01 |
| Completed | 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage Parkinson's Disease | Phase 3 | 2007-08-01 |
| Completed | Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson Parkinson's Disease | Phase 3 | 2007-01-01 |
| Completed | Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose Parkinson's Disease | Phase 3 | 2005-06-01 |
| Completed | Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose Idiopathic Parkinson's Disease | Phase 3 | 2004-12-01 |
| Completed | Phase II Dose Titration Study in Patients With Neuropathic Pain Neuropathic Pain | Phase 2 | 2004-05-01 |